Get started
Author

Daniele Frisone

Observed names: D. Frisone, Frisone, Daniele
Institution: Hôpital de la Tour
ORCID: 0000-0003-3737-3292
Observed ORCID: 0000-0003-3737-3292
OpenAlex ID: A5045924128
Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back
2025 · Annapaola Mariniello, Maxime Borgeaud, et al. · BioDrugs · 74
PDF
A BRAF new world
2020 · Daniele Frisone, Alex Friedlaender, et al. · Critical Reviews in Oncology/Hematology · 65
The Landscape of Immunotherapy Resistance in NSCLC
2022 · Daniele Frisone, Alex Friedlaender, et al. · Frontiers in Oncology · 64
PDF
The Role and Impact of Minimal Residual Disease in NSCLC
2021 · Daniele Frisone, Alex Friedlaender, et al. · Current Oncology Reports · 25
PDF
Durable response to palbociclib and letrozole in ovarian cancer withCDKN2Aloss
2019 · Daniele Frisone, Melinda Charrier, et al. · Cancer Biology & Therapy · 25
PDF
Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions
2022 · Daniele Frisone, Jose Sandoval, et al. · Cancer Epidemiology · 13
PDF
Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer
2023 · Alessandro Cucchetti, Benjamin Djulbegovic, et al. · Surgery · 8
PDF
Risk Factors for Arterial Thromboembolic Events in Male Germ Cell Tumors Treated with Chemotherapy
2025 · Daniele Frisone, Melinda Charrier, et al. · Cancers · 1
PDF
Side Effects of Cancer Immunotherapies: Dermatologic and Rheumatologic Toxicities
2023 · Daniele Frisone, Pierre O. Chappuis · Praxis · 1
Gender differences in cancer care experiences in Switzerland: a multicentre cross-sectional study
2026 · Anthony Pernoud, Angela Pugliesi Rinaldi, et al. · BMJ Open
PDF
133P Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions
2022 · D. Frisone, J. Sandoval, et al. · Annals of Oncology
Works count: 12
Citation count: 276
H-index: 7
I10-index: 6
Year
Topic
Type